In a report released yesterday, Reni Benjamin from Raymond James maintained a Hold rating on Audentes Therapeutics (NASDAQ: BOLD). The company’s shares closed yesterday at $36.64.
Benjamin wrote:
“We are maintaining our Market Perform rating for Audentes. Society (WMS), Audentes showcased longer-term data from the Phase I/II ASPIRO study assessing AT132 in patients with X-linked myotubular myopathy (XLMTM). Key takeaways include: 1) AT132 improved neuromuscular function and respiratory function, with 3 patients achieving complete ventilator independence; 2) AT132 continues to be safe and adverse events (AEs) remain largely manageable; and 3) the company also presented multiple posters demonstrating the validity of the CHOP-INTEND score in XLMTM, as well as findings from the INCEPTUS natural history study and the RECENSUS retrospective study.”
According to TipRanks.com, Benjamin is a 3-star analyst with an average return of 2.5% and a 40.3% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Alpine Immune Sciences Inc, Asterias Biotherapeutics, and Adaptimmune Therapeutics.
Audentes Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $40.
See today’s analyst top recommended stocks >>
Based on Audentes Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $31.37 million. In comparison, last year the company had a GAAP net loss of $25.01 million.
Based on the recent corporate insider activity of 22 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BOLD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Audentes Therapeutics, Inc. is a biotechnology company, which engages on development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. Its products include AT001 for the treatment of X-Linked Myotubular Myopathy, AT002 for the treatment of Pompe disease, and AT003 for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA.
